We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Mulungu – Rainforest Anxiolytic

Patocka Jiri

Department of Radiology and Toxicology, Faculty of Health and Social Studies
University of South Bohemia Ceske Budejovice
Czech Republic

1. Introduction

There are over one hundred species of plants of the genus *Erythrina* in the tropics and many of them are native to the American continent (Neill 1988). *Erythrina* species are known to produce alkaloids, flavonoids and terpenes (Garcia-Mateos et al., 1998). As with other species of *Erythrina*, alkaloids appear to be one of the main constituents mulungu (Parsons and Palframan, 2010). Mulungu (*Erythrina mulungu*) is a branched tree native to Brazil, growing in rain-forestry of Amazonia. Since its flowers are the same red color as coral, the plant is sometimes also called "flor de coral" and in English literature "coral tree". The designation *Erythrina* also includes the species *Erythrina velutina*, endemic to the semi-arid regions of Northeastern Brazil, and *Erythrina mulungu*, a plant native to Southern Brazil.

In native herbal medicine, a leaf or bark decoction or tincture from mulungu has long been used in folk medicine due to their tranquilizing effects and as natural sedative. It is also anxiolytic and antibacterial (Garín-Aguilar et al., 2000). In both Brazil and Peru mulungu is used for epilepsy (Vasconcelos et al., 2007). Practitioners in the United States use mulungu to quiet hysteria from trauma or shock, as a mild sedative to calm the nervous system, to treat insomnia and promote healthy sleeping patterns. Anxiety disorders are among the most prevalent psychiatric diseases and mulungu offers novel therapy chance (Balbani et al., 2009; Patocka, 2009). Latest the present results suggest that *Erythrina* has anxiolytic-like effects on a specific subset of defensive behaviors, particularly one that has been related in clinical terms to generalized anxiety. These observations support the popular use of extracts of the plant as tranquilizing agents.

2. Ethnobotany

Erythrina is a genus of flowering plants in the pea family, *Fabaceae*. It contains about 130 species, which are distributed in tropical and subtropical regions worldwide. They are trees, growing up to 30 m in height. The generic name is derived from the Greek word ερυθρός (*erythros*), meaning "red", referring to the flower color of certain species. These trees are religious for some ethnic minority and are used as floral emblems in many countries. For example Cockspur Coral Tree (*E. crista-galli*) is the national flower of Argentina and Uruguay. The Coastal Coral Tree (*E. caffra*) is the official city tree of Los Angeles, California. The state trees of Mérida and Trujillo in Venezuela are "bucaré ceibo" (*E. poeppigiana*) and Purple Coral Tree ("bucaré anauco", *E. fusca*), respectively. *E. variegata* is used as floral

emblem in Yonabaru, Okinawa. Some coral trees are used widely as street and park trees, especially in tropical countries. These trees are very suitable as "frame tree" for vanilla vines to grow up on or are used as "shade trees" in coffee or cocoa plantations (Westley and Powell, 1993). The plants of the genus *Erythrina* were used in Pre-Columbian America in traditional medicine (Towle, 2007) to calm agitation and for insomnia and other disorders of the nervous system.

3. Ethnopharmacology

Pharmacological assays performed with the alkaloids of *Erythrina americana* have shown anticonvulsant, hypnotic and analgesic effects (Garín-Aguilar et al., 2000; Koné et al., 2004). The species *Erythrina glauca* and *Erythrina lysistemon* have been reported to possess antiviral, antibacterial, and estrogenic activity (Ito, 1999; Tanee et al., 2007). Furthermore, analgesic and anti-inflammatory effects were observed for an aqueous extract of the stem bark of *Erythrina senegalensis* (Saidu et al., 2000).

Erythrina mulungu, tree high up to 10 m, is at home in South America. In Brasilia it is known as *colorines*, *chilicote* or *tzompanquahuitl* (Agra et al. 2007). In herbal medicine, a leaf or bark decoction or tincture from mulungu is considered to calm agitation and other disorders of the nervous system, including insomnia (Rodrigues and Carlini, 2003; Vasconcelos et al., 2007). Mulungu also decreased blood pressure and normalize heart arrhythmia (Begossi et al., 2004). There have also been some reports on the therapeutic use of the plant's inflorescence by herbal practitioners (Onusic et al. 2003). In Pre-Columbian civilizations decoction from the bark of this tree was used for suppression of fight fear and wartime hardship (Duke, 2008). At present, mulungu is used in the area of South America, mainly in Brasilia and Peru, as sedative and also in epilepsy (Teixeira-Silva et al., 2008).

People's healers and some practitioners in The United States use mulungu to quiet hysteria from trauma or shock, as a mild, hypnotic sedative to calm the nervous system, to treat insomnia and promote healthy sleeping patterns, to regulate heart palpitations, and to treat hepatitis and liver disorders. Nevertheless, despite its wide popular utilization, the supposed therapeutic properties of *Erythrina mulungu* only recently began to be evaluated in preclinical studies.

4. Chemistry of *Erythrina* constituents

The chemicals constituents of mulungu have been studied extensively after modern medical science find health potential of this biomedicine. In this biological material have been found large amounts of novel flavonoids, triterpenes, and alkaloids (Da-Cunha et al., 1996; Majinda et al., 2005; Cui et al., 2009). The genus *Erythrina* is very rich in secondary metabolites particularly of the flavonoids class. A literature survey showed the presence of flavanones, flavonols, chalcones, cinnamoylphenols, stilbenoids, isoflavones, isoflavans, isoflavanones, pterocarpanes, isoflav-3-enes, 3-phenoxychromones, coumestans, 3-phenylcoumarins, lignans, cinnamate esters, simple phenolics, triterpenes, sesquiterpenes, long-chain carboxylic acids, and long-chain alcohols (Majinda et al., 2005). Flavonoids represent a group of very active chemicals with various properties and are almost always present in *Erythrina* species.

The most considerable group of biologically active compounds of mulungu are alkaloids (Ozawa et al. 2009). The alkaloids have been found in 78 of 107 species in the genus

Erythrina; mulungu is documented with 20 isoquinoline alkaloids (Tanaka et al., 2008; Parsons and Palframan, 2010). The alkaloids accumulated not only at the end of maturation in the seeds but also in young tissues. On a dried basis, a high content of alkaloids was observed in flowers and dry seeds in comparison to low levels in dry pods. The highest concentrations were found in the mature seeds (García-Mateos et al., 1996). Many of these have demonstrated anti-inflammatory, cardioactive, narcotic, and sedative activities (Parsons and Palframan, 2010).

The pivotal structure of erythrinan alkaloids is tetraheterocyclic nitrogen compound with tetrahydroisoquinoline moiety called erythrinane (**I**) (Amer et al., 1991). Compounds of these structure were known for a long time (Koniuszy et al., 1949), but until medical science research of mulungu ignited concern over these alkaloids. Heft of erythrinan alkaloids are derivatives of **I** substituted at nucleus A and D by hydroxyl or alkoxy groups. The most considerable erythrinan alkaloids are erysotrine (**II**), erythravine (**III**), erysodine (**IV**), and erysopine (**V**) (Fig. 1) (Flausino et al., 2007a,b). For ever new erythrinan alkaloids are recovered (Tanaka et al., 2008; Cui et al., 2009, Parsons and Palframan, 2010).

Alkaloid	R ¹	R ²	R ³
I	H	H	H
II	OCH ₃	OCH ₃	OCH ₃
III	OCH ₃	OCH ₃	OH
IV	OH	OCH ₃	OCH ₃
V	OH	OH	OCH ₃

Fig. 1. Chemical structures of erythrinan alkaloids. Erythrinan alkaloids are derived from tetraheterocyclic nitrogen compound with tetrahydroisoquinoline moiety called erythrinane (**I**). Heft of erythrinan alkaloids are derivatives of **I** substituted at nucleus A and D by hydroxyl or alkoxy groups. The most considerable erythrinan alkaloids are erysotrine (**II**), erythravine (**III**), erysodine (**IV**), and erysopine (**V**).

5. Toxicology

Mulungu is relatively safe remedy. Acute oral toxicity (LD_{50}) of aqueous extract of stem bark of *E. variegata* was 425 mg/kg in mice (Pitchaiah et al., 2010). Lollato et al. (2010) estimated for extracts of *E. speciosa* LD_{50} value for mice as being higher than 2000 mg/kg.

The toxicity of chloroform stem bark extract of *Erythrina senegalensis* DC, a medicinal plant with anti-inflammatory activity, was studied in vivo and in vitro by Udem and co-workers (2010). The LD_{50} intraperitoneal of the extract was 526 mg/kg after an acute toxicity test (24 h). A brine shrimp lethality test with the extract gave LC_{50} of 60.86 ppm. The chronic studies revealed alterations in the levels of biochemical markers of hepatic and cardiac damage. The alterations were, however, not significant except in the group fed the highest inclusion of the extract (1.0 g extract/kg feed) where significant ($p < 0.05$) increases in the activities of alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were observed. Hematological assessments of mice in this group showed significant ($p < 0.05$) decreases in the red blood cell count and the packed cell volume. Increases in the relative weights of the liver and heart were also significant ($p < 0.05$). Lipid peroxidation product levels assayed as malondialdehyde was significantly ($p < 0.05$) elevated in the groups fed 0.5 and 1.0 g/kg of feed at day 84. Significant histopathological changes like myocardial hemorrhages and degeneration of hepatocytes were observed in the heart and liver respectively.

Mulungu is less toxic than most of synthetic tranquilizers, e.g. LD_{50} value for diazepam in mice at peroral administration is 49 mg/kg (Hogskilde et al., 1987). To evaluate the acute toxicity of the aqueous extract of *Erythrina velutina* leaves, which is frequently used in folk medicine as a tranquilizer, adult Wistar rats were treated *per os* with the limit dose of 5 g/kg of the extract and then observed for 14 consecutive days. No animals died and no signs of toxicity were detected either during the behavioral observations or at the autopsies, what indicates a reasonable lack of toxicity for the extract (Craveiro et al., 2010).

6. Biological activity

The traditional use of mulungu for anxiety and stress has been validated by researchers in a few studies, where it was shown to alter anxiety-related responses (Flausino et al. 2007a,b). An animal model (correlating to human generalized anxiety disorder, as well as panic disorder) was undertaken on a water-alcohol extract of mulungu (Vasconcelos et al. 2004; Ribeiro et al. 2006; Flausino et al. 2007a). Vasconcelos and co-workers (2004) studied the effects of hydroalcoholic extracts of both *Erythrina velutina* and *Erythrina mulungu* on the behavior of female mice submitted to the open-field test and to the elevated plus-maze after oral or intraperitoneal administration. The highest doses (800 mg/kg, oral, and 400 mg/kg, intraperitoneal) of the hydroalcoholic extracts decreased locomotor activity both in the open-field and in the elevated plus-maze test. The authors concluded that these results supported, at least in part, the popular use of the two species of *Erythrina* as tranquilizers in Brazilian folk medicine. Another study (Dantas et al., 2004) performed with intraperitoneal administration of an aqueous *Erythrina velutina* extract showed that the extract prolonged the duration of sleep induced by sodium pentobarbital at higher doses and blocked the acquisition of foot shock memory at lower doses. These results led the authors to propose that *Erythrina velutina* might interfere with the mnemonic process and might have a sedative action (Dantas et al., 2004).

The researchers reported that the mulungu extract had an effect similar to the commonly-prescribed anti-anxiety drug diazepam (Onusic et al. 2003; Ribeiro et al. 2006; Teixeira-Silva et al. 2008). Raupp and co-workers (2008) administered orally the hydroalcoholic extract of the stem bark of *Erythrina velutina* in mice submitted to the following tests: elevated plus-maze, forced swim, spontaneous locomotor activity, and habituation to active chamber. Chlordiazepoxide and imipramine were used as standard drugs. In the elevated plus-maze test, chronic, but not acute, *Erythrina velutina* (100 mg/kg) administration increased the percentage of open arm entries, an effect also seen in both acute and chronic treatments with chlordiazepoxide (7.5 mg/kg). In the forced swim test, only imipramine (25 mg/kg) decreased immobility time. Impairment of habituation was seen only with acute imipramine administration and with the lowest doses of *Erythrina velutina* extract tested in acute (10 mg/kg) and chronic (50 mg/kg) administrations. These results suggest that chronic administration of the hydroalcoholic extract of the stem bark of *Erythrina velutina* exerts an anxiolytic-like effect on mice, and it could serve as a new approach for the treatment anxiety, although it may have an amnesic effect at low doses.

It was suggested in many studies that the alkaloids in *Erythrina* may alter GABAergic neurotransmission (Ribeiro et al. 2006; Teixeira-Silva et al. 2008; Khanum and Razack, 2010). GABA acts as a neurotransmitter in the brain and abnormalities with its function is implicated in diseases including epilepsy, anxiety, and depression. Nevertheless, mechanism of anxiolytic effect of erythrina alkaloids is evidently different from diazepam. These alkaloids induced contractions seem to involve GABA_A receptor activation, acetylcholine release, muscarinic receptor activation, augmentation of Ca²⁺ entry through L-type calcium channels, and calcium release from the intracellular stores. These findings provide further support for *Erythrina velutina* traditional uses (Carvalho et al. 2009).

Hydroalcoholic extracts from the stem bark of *erythrina velutina* and *Eerythrina mulungu* have anticonvulsant effects only in the strychnine-induced seizure model, suggesting their possible action in glycine system and a potentiation of pentobarbital sleeping time, suggesting depressant action in the CNS (Vasconcelos et al. 2007). Data of Dantas and co-workers (2004) showed that the crude extract of *E. velutina* at lower doses interferes with mnemonic process for different tasks, while at higher doses, the sedative and neuromuscular blocking actions are the main effects. Anticonvulsant profile of erythrina alkaloids was recently studied by Faggion et al. (2011). They isolated the alkaloids (+)-erythravine and (+)-11- α -hydroxy-erythravine from the flowers of *Erythrina mulungu* and evaluated the action of these compounds against chemically induced seizures in rats (Faggion et al. 2011). These results showed that the administration of different doses of (+)-erythravine inhibited seizures evoked by bicuculline, pentylenetetrazole, and kainic acid at maximum of 80, 100, and 100%, respectively, whereas different doses of (+)-11- α -hydroxy-erythravine inhibited seizures at a maximum of 100% when induced by bicuculline, NMDA, and kainic acid, and, to a lesser extent, pentylenetetrazole (60%). All animals were protected against death when treated with different doses of (+)-11- α -hydroxy-erythravine in the tests using the four chemical convulsants. Identical results were obtained when using (+)-erythravine in the tests of bicuculline, NMDA, and pentylenetetrazole, and, to a lesser extent, kainic acid.

Further research has validated the traditional use of mulungu as an antimicrobial agent for throat and urinary infections. Mulungu has demonstrated antibacterial activity against *Escherichia coli*, *Staphylococcus aureus*, and antimycobacterial activity against *Mycobacterium fortuitum* and *M. smegmatis* (Virtuoso et al., 2005; Ferreira de Lima et al., 2006). Some

isoflavonoids, mainly erycristagallin (3,9-dihydroxy-2,10-di(gamma,gamma-dimethylallyl)-6a,11a-dehydropterocarpan), isolated from *Erythrina variegata* have antibacterial activity against cariogenic oral bacteria (Sato et al., 2003). The findings indicate that erycristagallin has a potential as potent phytochemical agent for prevention of dental caries by inhibiting the growth of cariogenic bacteria and by interfering with incorporation of glucose responsible for production of organic acids.

Two new compounds with antibacterial effect, erybacin A and erybacin B, were isolated from the roots of *Erythrina herbacea*. Their structures were established on the basis of spectroscopic analyses. Erybacin A is a rare, naturally occurring 1-hydroxy-1,3-diphenylpropan-2-one derivative. The isolated compounds were evaluated for their antibacterial activity against 13 strains of methicillin-resistant *Staphylococcus aureus* (MRSA). The new compound erybacin B showed a potent bactericidal activity against MRSA (Tanaka et al., 2010b).

Hydroalcoholic extracts from the stem bark and leaves of *Erythrina velutina* and *Erythrina mulungu* have also antinociceptive effects which was not reversed by naloxone, i.e. these are independent of the opioid system (Vasconcelos et al., 2003; Marchioro et al., 2005).

Alkaloid erysodine is a competitive antagonist at neuronal nicotinic acetylcholine receptors (Mansbach et al., 2000). The potent and competitive nature of erysodine's antagonism together with its ability to enter the brain after systemic administration suggest that erysodine may be a useful tool in characterizing neuronal nicotinic acetylcholine receptors (Decker et al., 1995). Recent findings show that erysodine and also dihydro-beta-erythroidine are potent and selective competitive inhibitors of alpha4beta2 nicotinic acetylcholine receptors (Iturriaga-Vásquez et al., 2010).

Erythrinan alkaloids cristanine A and cristanine B were isolated from the bark of *Erythrina crista-galli*. In Brazil, the bark of the title tree is used for the treatment of rheumatism and hepatitis as well as for sedation and hypnogenesis. However, the title alkaloids cristanine A and B are inactive concerning the inhibitory activity on lipopolysaccharide-induced nitric oxide production (Ozawa et al., 2010). Probably erythrinan alkaloids are also responsible for the antiinflammatory and analgesic effects of the ethanolic extract of *Erythrina indica* (Rajeev et al., 2010). *Erythrina indica* leaves are traditionally used in Kerala to treat inflammation, ulcers, earache etc.

7. Current practical use of *Erythrina*

Mulungu, drug from the tree *Erythrina mulungu*, is not very widely known or used in advanced countries. Mostly appearing as an ingredient in only a few herbal formulas for anxiety or depression. *Erythrina* plants produce alkaloids, flavonoids and terpenes and are commonly used in folk medicine due to their tranquilizing effects. Currently, the most widely prescribed medications for anxiety disorders are benzodiazepines. However, the clinical uses of benzodiazepines are limited by their side effects such as psychomotor impairment, potentiation of other central depressant drugs and dependence liability. Therefore, the development of new medications processing anxiolytic effect without the complications of benzodiazepines would be of great importance in the treatment of anxiety related disorders.

The use of herbal medicines by physicians in Europe, Asia, and America, exploring their traditional remedies to find a suitable cure of these 'mind affecting diseases' and herbal medicines are often considered to be gentle and safe alternative to synthetic drugs. Nevertheless, till this time no relevant clinical study exist.

Recently many studies of other *Erythrina* species from different parts of world appeared. These studies show that bioactive products of these trees may be useful in modern medicine also in other statements. From the bark of *Erythrina addisoniae* new flavonoids of stilbenoid type were isolated. These compounds are strong inhibitors of viral neuraminidases. Quite new compound, which is a formylated stilbenoid derivative, exhibited strong inhibition of both influenza H1N1 and H9N2 neuraminidases with IC₅₀ values of $8.80 \pm 0.34 \mu\text{g/mL}$ and $7.19 \pm 0.40 \mu\text{g/mL}$, respectively (Nguyen et al., 2010).

From the bark of *Erythrina abyssinica* has been isolated new coumestans and benzofurans with stimulatory effects on AMP-activated protein kinase (AMPK) (Nguyen et al., 2010) which has been proposed as a therapeutic target for the treatment of metabolic syndrome including obesity and type-2 diabetes. These results suggest that benzofurans and coumestans may be new lead compounds for regulating the AMPK enzyme. Prenylated flavanones from the same of source inhibited protein tyrosine phosphatase PTP1B activity in an *in vitro* assay with IC₅₀ values ranging from 15.2 ± 1.2 to $19.6 \pm 2.3 \mu\text{M}$, whereas very known potent inhibitor of PTP1B known as RK-682 (Hamaguchi et al., 1995) used as a positive control displayed an IC₅₀ value of $4.7 \pm 0.5 \mu\text{M}$ (Long et al., 2010).

Two new dimethylpyrano-isoflavones, named erymildbaedin A and B, were isolated from the stem bark of *Erythrina mildbraedi* - Cameroonian medicinal plant. Some of them strongly inhibited the growth of human breast, prostate, and endometrial adenocarcinoma cell lines (Tchokouaha et al. 2010).

Another flavonoids with the antibacterial activity were isolated from *Erythrina caffra*, deciduous subtropical tree indigenous to South Africa. All the compounds were active against both Gram-negative and Gram-positive bacteria. The minimum inhibitory concentration values obtained (MIC) ranged from $3.9 \mu\text{g/mL}$ to $125 \mu\text{g/mL}$ (Chukwujekwu et al., 2010). A new bis-isoflavonoid, biseryvarin A, was isolated from the roots of *Erythrina variegata*. Biseryvarin A is the first dimeric isoflavonoid possessing isoprenoid groups from the genus *Erythrina*. Biseryvarin A showed low activity MRSA. The methanol extract of the bark of *Erythrina variegata* showed significant anti-malarial activity toward *Plasmodium falciparum* *in vitro* using the lactate dehydrogenase assay. The ethyl acetate fraction showed the most activity, exhibiting equipotency against both strains of parasite with IC₅₀ of $23.8 \mu\text{g/mL}$ against 3D7 and $9.3 \mu\text{g/mL}$ against K1. Furthermore, by using the anti-malarial activity to follow separation, the ethyl acetate fraction was separated by combination of column chromatography to yield an active compound. The chemical structure of active compound was determined on the basis of spectroscopic evidences and comparison with those previously reported and identified as an isoflavonoid, warangalone. The warangalone showed anti-malarial activity against both strains of parasite used with IC₅₀ of $4.8 \mu\text{g/mL}$ against 3D7 and $3.7 \mu\text{g/mL}$ against K1 (Herlina et al., 2009). Next flavonoids were isolated from *Erythrina vogelii*, a Cameroonian medicinal plant (Ali et al. 2010), in *Erythrina senegalensis* were found hepatoprotective flavonoids (Njayou et al., 2010) with low toxicity (Atsamo et al., 2010). Flavonoids of pterocarpane-type with antibacterial, antiplasmodial and cytotoxic activities, were isolated from the stems of *Erythrina fusca* (Innok et al., 2010).

8. References

Agra MF, Baracho GS, Nurit K, Basilio IJLD, Coelho VPM. Medicinal and poisonous diversity of the flora of "Cariri Paraibano", Brazil J Ethnopharmacol 2007; 111: 383-395.

- Ali MI, Ahmed Z, Waffo AF, Ali MS. Flavonoids from *Erythrina vogelii* (Fabaceae) of Cameroon. *Nat Prod Commun*. 2010; 5(6): 889-892.
- Amer ME, Sharmma M, Freyer AJ. The tetracyclic erythrina alkaloids. *J Nat Prod* 1991; 54(2): 329-363.
- Atsamo AD, Nguelefack TB, Datté JY, Kamanyi A. Acute and subchronic oral toxicity assessment of the aqueous extract from the stem bark of *Erythrina senegalensis* DC (Fabaceae) in rodents. *J Ethnopharmacol*, Article in Press.
- Balbani AP, Silva DH, Montovani JC. Patents of drugs extracted from Brazilian medicinal plants. *Expert Opin Ther Pat* 2009; 19(4): 461-473.
- Begossi A, Hanazaki N, Tamashiro JY. Medicinal plants in the atlantic forest (Brazil): knowledge, use, and conservation. *Human Ecology* 2004; 30: 281-299.
- Carvalho AC, Almeida DS, Melo MG, Cavalcanti SC, Marçal RM. Evidence of the mechanism of action of *Erythrina velutina* Willd (Fabaceae) leaves aqueous extract. *J Ethnopharmacol* 2009; 122: 374-378.
- Chukwujekwu JC, Van Heerden FR, Van Staden J. Antibacterial activity of flavonoids from the stem bark of *Erythrina caffra* thunb. *Phytother Res* 2010; 25(1): 46-48.
- Craveiro ACS et al. Toxicidade aguda do extrato aquoso de folhas de *Erythrina velutina* em animais experimentais. *Rev. Bras. Farmacogn*. 2008; 18: 739-743.
- Cui L, Thuong PT, Fomum ZT, Oh WK. A new erythrinan alkaloid from the seed of *Erythrina addisoniae*. *Arch Pharm Res* 2009; 11(10): 233-2241.
- Da-Cunha EV, Dias C, Barbosa-Filho JM, Gray AI. Eryvellutinone, an isoflavone from the stem bark of *Erythrina vellutina*. *Phytochemistry* 1996; 43(6): 1371-1373.
- Dantas MC, De Oliveira FS, Bandeira SM, Batista JS, Silva CD Jr, Alves PB, Antonioli AR, Marchioro M. Central nervous system effects of the crude extract of *Erythrina velutina* on rodents. *J Ethnopharmacol*. 2004; 94(1): 129-133.
- Decker MW, Anderson DJ, Brioni JD, Donnelly-Roberts DL, Kang CH, O'Neill AB, Piattoni-Kaplan M, Swanson S, Sullivan JP. Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. *Eur J Pharmacol* 1995; 280(1): 79-89.
- Duke JA. *Dukes Handbuch of Medicinal Plants of Latin America*. CRC Press, 2008, 832 s. ISBN 1420043161
- Faggion SA, Cunha AO, Fachim HA, Gavin AS, Dos Santos WF, Pereira AM, Belebani RO. Anticonvulsant profile of the alkaloids (+)-erythravine and (+)-11- α -hydroxy-erythravine isolated from the flowers of *Erythrina mulungu* Mart ex Benth (Leguminosae-Papilionaceae). *Epilepsy Behav* 2011 Feb 1. [Epub ahead of print]
- Ferreira de Lima MR, de Souza Luna J, dos Santos AF, Caño de Andrade MC, Goulart SantAna AE, Genet JP, Marquez B, Neuville L, Moreau N. Anti-bacterial activity of some Beazilian medicinal plants. *J Ethnopharmacol* 2006; 105(1-2): 137-147.
- Flausino OA, de Avila Santos L, Verli H, Pereira AM, Bolzani VS, Nunes-de-Souza RL. Anxiolytic effects of erythrinian alkaloids from *Erythrina mulungu*. *J Nat Prod* 2007b; 70: 48-53.
- Flausino OA, Pereira AM, da Silva Bolzani V, Nunes-de-Souza RL Effects of erythrinian alkaloids isolated from *Erythrina mulungu* (Papilionaceae) in mice submitted to animal models of anxiety. *Biol Pharm Bull* 2007a; 30: 375-378.

- García-Mateos R, Lucas B., Zendejas M, Soto-Hernández M, Martínez M, Sotelo A. Variation of total nitrogen, non-protein nitrogen content, types of alkaloids at different stages of development in *Erythrina americana* seeds. J Agric Food Chem 1996; 44(10): 2987-2991.
- García-Mateos R, Soto-Hernández M, Kelly D. Alkaloids from six *Erythrina* species endemic to Mexico. Biochem System Ecol 1998; 26: 545-551.
- Garín-Aguilar MA, Luna JER, Soto-Hernández M, Valencia del Toro G, Vásquez MM. Effect of crude extracts of *Erythrina americana* Mill. on aggressive behavior in rats. J. Ethnopharmacol 2000; 69: 189-196.
- Hamaguchi T, Sudo T, Osada H. RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1 phase. FEBS Lett 1995; 372(1): 54-58.
- Herlina T, Supratman U, Soedjanaatmadja MS, Subarnas A, Sutardjo S, Abdullah NR, Hayashi H. Anti-malarial compound from the stem bark of *Erythrina variegata*. Indo J Chem 2009; 9(2): only on-line
<http://pdm-mipa.ugm.ac.id/ojs/index.php/ijc/article/viewArticle/526>
- Hogskilde S, Nielsen JW, Carl P., Angelo H, Bredgaard Sorensen M. The anticonvulsive activity and toxicity of diazepam in three different formulations. An experimental study in mice. Acta Anaesth Scand 1987; 31(4): 289-291.
- Innok P, Rukachaisirikul T, Phongpaichit S, Suksamrarn A. Fuscocarpan A - C, new pterocarpan from the stems of *Erythrina fusca*. Fitoterapia 2010; 81(6): 518-523.
- Ito K. Studies on the alkaloids of *Erythrina* plants. [Article in Japanese] Yakugaku Zasshi. 1999; 119(5): 340-356.
- Iturriaga-Vásquez P, Carbone A, García-Beltrán O, Livingstone PD, Biggin PC, Cassels BK, Wonnacott S, Zapata-Torres G, Bermudez I. Molecular determinants for competitive inhibition of $\alpha 4\beta 2$ nicotinic acetylcholine receptors. Mol Pharmacol 2010; 78(3): 366-375.
- Khanum F, Razack S. Anxiety – Herbal treatment: A review. Res Rev Biomed Biotech 2010; 1(2): 83-89.
- Koné WM, Atindehou KK, Terreaux C, Hostettmann K, Traoré D, Dosso M. Traditional medicine in north Côte-d'Ivoire: screening of 50 medicinal plants for antibacterial activity. J Ethnopharmacol 2004; 93(1): 43-49.
- Koniuszy F, Wiley PF, Folkers K. *Erythrina* alkaloids; studies on the constitution of erysodine erysovine and erysopine. J Am Chem Soc 1949; 71:875-878.
- Lollato G, Scarminio IS, Moreira EG. Behavioral effects of aqueous and dichloromethane extracts of *Erythrina speciosa* Andrews, Fabaceae, leaves in mice. Rev Bras Farmacognosia 2010; 20(6): 939-944.
- Long C, Sun LH, Tantoh ND, Tanyi MJ, Ho KY, Van LT, Hung NP, Keun OW. New prenylated flavanones from *Erythrina abyssinica* with protein tyrosine phosphatase 1B (PTP1B) inhibitory activity. Planta Medica 2010; 76(7): 713-718.
- Majinda RRT, Wanjala CCW, Juma BF. Bioactive non-alkaloidal constituents from the genus *Erythrina*. Stud Natural Prod Chem 2005; 32(12): 821-853.

- Mansbach RS, Chambers LK, Rovetti CC. Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. *Psychopharmacology (Berl)* 2000; 148(3): 234-242.
- Marchioro M, Blank Mde F, Mourão RH, Antoniolli AR. Anti-nociceptive activity of the aqueous extract of *Erythrina velutina* leaves. *Fitoterapia* 2005; 76(7-8): 637-642.
- Neill DA. Experimental studies on species relationships in *Erythrina* (Leguminosae: Papilionoideae). *Ann Missouri Botanical Garden*, 1988; 75: 886-969.
- Nguyen PH, Na M, Dao TT, Ndinteh DT, Mbafor JT, Park J, Cheong H, Oh WK. New stilbenoid with inhibitory activity on viral neuraminidases from *Erythrina addisoniae*. *Bioorg Med Chem Lett* 2010; 20(22): 6430-6434.
- Nguyen PH, Nguyen TNA, Dao TT, Kang HW, Ndinteh DT, Mbafor JT, Oh WK. AMP-Activated protein kinase (AMPK) activation by benzofurans and coumestans isolated from *Erythrina abyssinica*. *J Nat Prod*. 2010; 73(4): 598-602.
- Njayou F, Moundipa P, Donfack J, Chuisseu D, Tchana A, Ngadjui B, Tchouanguep F. Hepato-protective, antioxidant activities and acute toxicity of a stem bark extract of *Erythrina senegalensis* DC. *I J Biol Chem Sci* 2010; 4(3): only on-line <http://www.ajol.info/index.php/ijbcs/article/view/60503>
- Onusic GM, Nogueira RL, Rereira AMS, Flausino OA, Jr., de Barros Viana M. Effects of chronic treatment with a water-alcohol extrat from *Erythrina mulungu* on anxiety-related response in rats. *Biol Pharm Bull* 2003; 26(11): 1538-1542.
- Ozawa M, Etoh T, Hayashi M, Komiyama K, Kishida A, Ohsaki A. TRAIL-enhancing activity of Erythrinan alkaloids from *Erythrina velutina*. *Bioorg Med Chem Lett* 2009;19:234-236.
- Ozawa M, Kawamata S, Etoh T, Hayashi M, Komiyama K, Kishida A, Kuroda C, Ohsaki A. Structure of new erythrinan alkaloids and nitric oxide production inhibitors from *Erythrina crista-galli*. *Chem Pharm Bull* 2010; 58: 1119-1122.
- Parsons AF, Palframan MJ. *Erythrina* and related alkaloids. *Alkaloids Chem. Biol.* 68, 39-81, 2010.
- Patocka J. Mulungu - Anxiolytics from an Amazonian rainforest. [Article in Czech]. *Psychiatrie* 2009; 13: 89-91.
- Pitchaiah G, Viswanatha GL, Srinath R, Nandakumar K, Dayabaran D, Florance EJ. Anxiolytic and anticonvulsant activity of aqueous extract of stem bark of *Erythrina variegata* in rodents. *Int J Parm Tech Res* 2010; 2(1): 40-48.
- Rajeev VE, Latha PG, Anuja GI, Suja SR, Sini S, Shine VJ, Shyamal S, Krishnakumar NM, Shikha P, Liji J, Rajasekharan S. Antiinflammatory and analgesic properties of *Erythrina indica* Lamb. *Med Plants* 2010; 2(3):
- Raupp IM, Sereniki A, Virtuoso S, Ghislandi C, Cavalcanti e Silva EL, Trebien HA, Miguel OG, Andreatini R. Anxiolytic-like effect of chronic treatmemnt with *Erythrina velutina* extract in the elevated plus-maze test. *J Ethopharmacol* 2008; 118(2): 295-299.
- Ribeiro MD, Onusic GM, Poltronieri SC, Viana MB. Effect of *Erythrina velutina* and *Erythrina mulungu* in rats submitted to animal models of anxiety and depression. *Braz J Med Biol Res* 2006; 39: 263-270.

- Rodrigues E, Carlini E: Possíveis efeitos de plantas utilizadas por duas culturas brasileiras (quilombolas e índios) sobre o sistema nervoso central. *Arq Bras Fitomed Cien* 2003; 1: 147-154.
- Saidu K, Onah J, Orisadipe A, Olusola A, Wambebe C, Gamaniel K. Antiplasmodial, analgesic, and anti-inflammatory activities of the aqueous extract of the stem bark of *Erythrina senegalensis*. *J Ethnopharmacol* 2000; 71(1-2): 275-280.
- Sato M, Tanaka H, Fujiwara S, Hirata M, Yamaguchi R, Etoh H, Tokuda C. Antibacterial property of isoflavonoids isolated from *Erythrina variegata* against cariogenic oral bacteria. *Phytomedicine* 2003; 10(5): 427-433.
- Tanaka H, Hattori H, Tanaka T, Sakai E, Tanaka N, Kulkarni A, Etoh H. A new *Erythrina* alkaloid from *Erythrina herbacea*. *Nat Med (Tokyo)* 2008; 62: 228-231.
- Tanaka H, Sudo M, Hirata M, Etoh H, Sato M, Yamaguchi R, Sakai E, Chen IS, Fukai T. A new biisoflavonoid from the roots of *Erythrina variegata*. *Nat Prod Commun*. 2010; 5(11): 1781-1784.
- Tanaka H, Sudo M, Kawamura T, Sato M, Yamaguchi R, Fukai T, Sakai E, Tanaka N. Antibacterial constituents from the roots of *Erythrina herbacea* against methicillin-resistant *Staphylococcus aureus*. *Planta Med*. 2010b; 76(9): 916-919.
- Tanee FS, Njamen D, Magne NCB, Wanji J, Zierau O, Fomum ZT, Vollmer G. Estrogenic effects of the ethyl-acetate extract of the stem bark of *Erythrina lysistemon* Hutch (Fabaceae). *Phytomedicine* 2007; 14(2-3): 222-226.
- Teixeira-Silva F, Santos FN, Sarasqueta DFO, Alves MFS, Neto VA, Moreira de Paula C, Santos Estevan C, Antonioli AR, Marchioro M. Benzodiazepine-like effects of the alcohol extract from *Erythrina velutina* leaves: Memory, anxiety, and epilepsy. *Pharm Biol* 2008; 46: 321-328.
- Towle MA. The Ethnobotany of Pre-Columbian Peru. Transaction Publisher, Rutgers, The State University, 2007. 180 pages. ISBN: 978-0-202-30930-9.
- Vasconcelos SM, Lima NM, Sales GT, Cunha GM, Aguiar LM, Silveira ER, Rodrigues AC, Macedo DS, Fonteles MM, Sousa FC, Viana GS. Anticonvulsant activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu*. *J Ethnopharmacol* 2007; 110(2): 271-274.
- Vasconcelos SM, Macedo DS, de Melo CT, Paiva Monteiro A, Rodrigues AC, Silveira ER, Cunha GM, Sousa FC, Viana GS. Central activity of hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice. *J Pharm Pharmacol* 2004; 56(3): 389-393.
- Vasconcelos SM, Rebouças Oliveira G, Mohana de Carvalho M, Rodrigues AC, Rocha Silveira E, Maria França Fonteles M, Florenço Sousa FC, Barros Viana GS. Antinociceptive activities of the hydroalcoholic extracts from *Erythrina velutina* and *Erythrina mulungu* in mice. *Biol Pharm Bull* 2003; 26(7): 946-949.
- Udem SC, Obidoa O, Asuzu IU. Acute and chronic toxicity studies of *Erythrina senegalensis* DC stem bark extract in mice. *Comp Clin Pathol* 2010; 19(3): 275-282.
- Virtuoso S, Davet A, Dias JFG, Cunico MM, Miguel MD, Oliveira AB, Miguel OG. Preliminary study of the antibacterial activity of *Erythrina velutina* Willd. Fabaceae (Leguminosae) bark. [Article in Portuguese] *Rev Bras Farmacogn* 2005; 15(2): 137-142.

Westley SS, Powell MH. Erythrina in the New and Old Worlds. NFTR Special Issue, Bangkok, 1993, 370 pages. ISBN: 974-8434-55-9.

IntechOpen

IntechOpen

Anxiety and Related Disorders

Edited by Dr. Ágnes Szirmai

ISBN 978-953-307-254-8

Hard cover, 292 pages

Publisher InTech

Published online 29, August, 2011

Published in print edition August, 2011

Anxiety disorders are one of the most common psychiatric disorders worldwide and many aspects of anxiety can be observed. Anxious patients often consult primary care physicians for their treatment, but in most cases they do not accept the diagnosis of anxiety disorder. Anxiety is a symptom that could be seen in many organic disorders and can accompany almost any psychiatric disorder. Anxiety disorders are frequent and are associated with significant distress and dysfunction. Stigmatization is an important factor in insufficient diagnosis. The problems of anxiety cover all fields of life. This book intends to describe the epidemiological aspects and the main co-morbidities and consecutive diseases of the anxiety disorders.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Patocka Jiri (2011). Mulungu – Rainforest Anxiolytic, *Anxiety and Related Disorders*, Dr. Ágnes Szirmai (Ed.), ISBN: 978-953-307-254-8, InTech, Available from: <http://www.intechopen.com/books/anxiety-and-related-disorders/mulungu-rainforest-anxiolytic>

INTech
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen